NasdaqCM:ATOS

Stock Analysis Report

Executive Summary

Atossa Genetics Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.

Risks

  • Atossa Genetics has significant price volatility in the past 3 months.
  • Atossa Genetics is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Atossa Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.6%

NasdaqCM:ATOS

1.9%

US Medical Equipment

2.1%

US Market


1 Year Return

-4.1%

NasdaqCM:ATOS

13.6%

US Medical Equipment

-0.04%

US Market

ATOS underperformed the Medical Equipment industry which returned 14% over the past year.

ATOS underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

ATOSIndustryMarket
7 Day-4.6%1.9%2.1%
30 Day2.0%-0.2%-3.2%
90 Day-20.0%10.2%2.8%
1 Year-4.1%-4.1%14.5%13.6%2.2%-0.04%
3 Year-94.2%-94.2%70.2%65.0%41.5%32.3%
5 Year-99.4%-99.4%133.6%106.8%55.0%37.8%

Price Volatility Vs. Market

How volatile is Atossa Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atossa Genetics undervalued based on future cash flows and its price relative to the stock market?

1.12x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Atossa Genetics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Atossa Genetics to establish if it is available at substantial discount.


Price Based on Earnings

Atossa Genetics is loss making, we can't compare its value to the US Medical Equipment industry average.

Atossa Genetics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Atossa Genetics, we can't assess if its growth is good value.


Price Based on Value of Assets

Atossa Genetics is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Atossa Genetics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

61.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Atossa Genetics is high growth as no revenue estimate data is available.

Atossa Genetics's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Atossa Genetics's revenue growth to the United States of America market average as no estimate data is available.

Atossa Genetics's earnings growth is expected to exceed the United States of America market average.

Atossa Genetics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Atossa Genetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Atossa Genetics performed over the past 5 years?

-13.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Atossa Genetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Atossa Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Atossa Genetics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Atossa Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Atossa Genetics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Atossa Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Atossa Genetics's financial position?


Financial Position Analysis

Atossa Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Atossa Genetics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Atossa Genetics has no debt.

Atossa Genetics currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Atossa Genetics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Atossa Genetics has sufficient cash runway for 1.8 years based on current free cash flow.

Atossa Genetics has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 6.6% each year.


Next Steps

Dividend

What is Atossa Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Atossa Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Atossa Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Atossa Genetics has not reported any payouts.

Unable to verify if Atossa Genetics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Atossa Genetics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Atossa Genetics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Atossa Genetics's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Steve Quay (68yo)

10.3yrs

Tenure

US$1,881,344

Compensation

Dr. Steven C. Quay, also known as Steve, M.D., Ph.D., FCAP has been the Chief Executive Officer and President of Atossa Genetics, Inc. since April 30, 2009 and served as its Chief Financial Officer since A ...


CEO Compensation Analysis

Steve's remuneration is higher than average for companies of similar size in United States of America.

Steve's compensation has increased whilst company is loss making.


Management Age and Tenure

4.6yrs

Average Tenure

The tenure for the Atossa Genetics management team is about average.


Board Age and Tenure

5.6yrs

Average Tenure

65yo

Average Age

The tenure for the Atossa Genetics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Steve Quay (68yo)

    Chairman

    • Tenure: 10.3yrs
    • Compensation: US$1.88m
  • Kyle Guse (55yo)

    CFO, General Counsel & Secretary

    • Tenure: 6.6yrs
    • Compensation: US$905.33k
  • Janet Rea

    Senior Vice President of Regulatory

    • Tenure: 1.6yrs
  • Jack Cuzick

    Member of Scientific Advisory Board

    • Tenure: 2.7yrs

Board Members

  • Rich Steinhart (62yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: US$172.64k
  • Greg Weaver (63yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: US$172.64k
  • Steve Quay (68yo)

    Chairman

    • Tenure: 10.3yrs
    • Compensation: US$1.88m
  • Larry Remmel (67yo)

    Independent Director

    • Tenure: 7.5yrs
    • Compensation: US$92.64k
  • Carl Novina

    Scientific Advisor

    • Tenure: 1.7yrs
  • Shu-Chih Chen (57yo)

    Director

    • Tenure: 10.3yrs
    • Compensation: US$142.64k
  • Stephen Galli (72yo)

    Independent Director

    • Tenure: 8.1yrs
    • Compensation: US$167.64k
  • Bob Miglani

    Member of Strategic Advisory Board

    • Tenure: 1.3yrs
  • Jack Cuzick

    Member of Scientific Advisory Board

    • Tenure: 2.7yrs
  • Per Hall

    Scientific Advisor

    • Tenure: 1.4yrs

Company Information

Atossa Genetics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atossa Genetics Inc.
  • Ticker: ATOS
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$18.989m
  • Shares outstanding: 9.13m
  • Website: https://www.atossagenetics.com

Number of Employees


Location

  • Atossa Genetics Inc.
  • 107 Spring Street
  • Seattle
  • Washington
  • 98104
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATOSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2012
YAG2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2012
YAG2BST (Boerse-Stuttgart)YesCommon StockDEEURNov 2012

Biography

Atossa Genetics Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Its lead program is the development of Endoxifen, con ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 00:24
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.